Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Although it has been suggested that pulmonary tuberculosis (TB) is associated with increased risk of lung cancer, the exact mechanism is not clearly identified. We investigated the effect of pulmonary TB on the epidermal growth factor receptor (EGFR) mutational status and clinical outcome in patients with pulmonary adenocarcinoma. Materials and Methods We reviewed data of patients diagnosed with pulmonary adenocarcinoma harboring EGFR mutations and treated at our institution from 2008 to 2015. We divided our population into two groups: patients with pre-existing TB lesions on chest computed tomography scan (TB group) and those without the lesions (non-TB group). We compared the differences in EGFR mutational status, response to tyrosine kinase inhibitors (TKIs) and survival between the two groups. Results A total of 477 patients with pulmonary adenocarcinoma were analyzed. One hundred eightythree patients (39%) had EGFR-mutated tumors and 100 (21%) patients had pre-existing TB lesions. The frequency of EGFR mutation was significantly higher in the TB group compared with the non-TB group (56% vs. 34%, p=0.038). Pre-existing TB lesions were independently associated with more frequent EGFR mutations in multivariate analysis (odds ratio, 1.43). In addition, both the progression-free survival (9.1 months vs. 11.6 months, p=0.020) and the overall survival (19.4 months vs. 24.5 months, p=0.014) after first-line EGFR-TKIs were significantly shorter in the TB group than in the non-TB group. Conclusion Previous pulmonary TB may be associated with more frequent EGFRmutations and poorer treatment response to EGFR-TKIs in patients with pulmonary adenocarcinoma.
Abstract
Purpose Although it has been suggested that pulmonary tuberculosis (TB) is associated with increased risk of lung cancer, the exact mechanism is not clearly identified. We investigated the effect of pulmonary TB on the epidermal growth factor receptor (EGFR) mutational status and clinical outcome in patients with pulmonary adenocarcinoma. Materials and Methods We reviewed data of patients diagnosed with pulmonary adenocarcinoma harboring EGFR mutations and treated at our institution from 2008 to 2015. We divided our population into two groups: patients with pre-existing TB lesions on chest computed tomography scan (TB group) and those without the lesions (non-TB group). We compared the differences in EGFR mutational status, response to tyrosine kinase inhibitors (TKIs) and survival between the two groups. Results A total of 477 patients with pulmonary adenocarcinoma were analyzed. One hundred eightythree patients (39%) had EGFR-mutated tumors and 100 (21%) patients had pre-existing TB lesions. The frequency of EGFR mutation was significantly higher in the TB group compared with the non-TB group (56% vs. 34%, p=0.038). Pre-existing TB lesions were independently associated with more frequent EGFR mutations in multivariate analysis (odds ratio, 1.43). In addition, both the progression-free survival (9.1 months vs. 11.6 months, p=0.020) and the overall survival (19.4 months vs. 24.5 months, p=0.014) after first-line EGFR-TKIs were significantly shorter in the TB group than in the non-TB group. Conclusion Previous pulmonary TB may be associated with more frequent EGFRmutations and poorer treatment response to EGFR-TKIs in patients with pulmonary adenocarcinoma.
참고문헌 (30)
- Bray F, "Global cancer transitions according to the Human Development Index(2008-2030) : a population-based study", Lancet Oncol, 13, pp.790~801 (2012)
- 박지영, "Epidemiology of Lung Cancer in Korea: Recent Trends", Tuberculosis and Respiratory Diseases, 79(2), pp.58~69 (2016), 대한결핵및호흡기학회
- Brenner DR, "Previous lung diseases and lung cancer risk : a pooled analysis from the International Lung Cancer Consortium", Am J Epidemiol, 176, pp.573~585 (2012)
- Hubbard R, "Lung cancer and cryptogenic fibrosing alveolitis : a population-based cohort study", Am J Respir Crit Care Med, 161, pp.5~8 (2000)
- Durham AL, "The relationship between COPD and lung cancer", Lung Cancer, 90, pp.121~127 (2015)
- "Global tuberculosis report 2017" (2017)[URL]
- Hong S, "Tuberculosis, smoking and risk for lung cancer incidence and mortality", Int J Cancer, 139, pp.2447~2455 (2016)
- Wu CY, "Pulmonary tuberculosis increases the risk of lung cancer : a population-based cohort study", Cancer, 117, pp.618~624 (2011)
- Everatt R, "Inci-dence of lung cancer among patients with tuberculosis : a nationwide cohort study in Lithuania", Int J Tuberc Lung Dis, 20, pp.757~763 (2016)
- Moghaddam SJ, "Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-rasinduced mouse model", Am J Respir Cell Mol Biol, 40, pp.443~453 (2009)
- Nalbandian A, "Lung carcinogenesis induced by chronic tuberculosis infection : the experimental model and genetic control", Oncogene, 28, pp.1928~1938 (2009)
- Jett JR, "Targeted therapy for non-small cell lung cancer", Am J Respir Crit Care Med, 188, pp.907~912 (2013)
- Shi Y, "A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology(PIONEER)", J Thorac Oncol, 9, pp.154~162 (2014)
- Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
- Rosell R, "Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial", Lancet Oncol, 13, pp.239~246 (2012)
- Sequist LV, "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations", J Clin Oncol, 31, pp.3327~3334 (2013)
- 장윤수, "Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma", Tuberculosis and Respiratory Diseases, 79(4), pp.248~256 (2016), 대한결핵및호흡기학회
- Casalino-Matsuda SM, "Epidermal growth factor receptor activation by epidermal growth factor mediates oxidant-induced goblet cell metaplasia in human airway epithelium", Am J Respir Cell Mol Biol, 34, pp.581~591 (2006)
- Zhang J, "Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells", Cancer Prev Res(Phila), 1, pp.201~207 (2008)
- 황기은, "Response Evaluation of Chemotherapy for Lung Cancer", Tuberculosis and Respiratory Diseases, 80(2), pp.136~142 (2017), 대한결핵및호흡기학회
- Kim YI, "Coexisting bronchogenic carcinoma and pulmonary tuberculosis in the same lobe : radiologic findings and clinical significance", Korean J Radiol, 2, pp.138~144 (2001)
- Kim TJ, "Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage", J Surg Oncol, 110, pp.245~251 (2014)
- Denholm R, "Is previous respiratory disease a risk factor for lung cancer?", Am J Respir Crit Care Med, 190, pp.549~559 (2014)
- Liang HY, "Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk : a systematic review", Int J Cancer, 125, pp.2936~2944 (2009)
- Yu YH, "Increased lung cancer risk among patients with pulmonary tuberculosis : a population cohort study", J Thorac Oncol, 6, pp.32~37 (2011)
- Cicenas S, "Lung cancer in patients with tuberculosis", World J Surg Oncol, 5, pp.22~ (2007)
- Luo YH, "Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs", J Thorac Oncol, 7, pp.299~305 (2012)
- 이승헌, "Tuberculosis Infection and Latent Tuberculosis", Tuberculosis and Respiratory Diseases, 79(4), pp.201~206 (2016), 대한결핵및호흡기학회
- Yu YY, "Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial", Arch Intern Med, 168, pp.2326~2332 (2008)
- Chang CH, "Gender-based impact of epidermal growth factor receptor mutation in patients with nonsmall cell lung cancer and previous tuberculosis", Medicine (Baltimore), 94, pp.e444~ (2015)